Milestone Pharmaceuticals (MIST) Preferred Stock Liabilities (2018 - 2019)
Milestone Pharmaceuticals' (MIST) quarterly Preferred Stock Liabilities came in at -$64.7 million in Q2 2019, down 611.9% YoY from $12.6 million in Q2 2018, and down 476.32% on a QoQ basis from $17.2 million in Q1 2019.
Milestone Pharmaceuticals (MIST) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 2 years of Preferred Stock Liabilities data on file, last reported at -$64.7 million in Q2 2019.
- Quarterly Preferred Stock Liabilities fell 611.9% year-over-year to -$64.7 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was -$64.7 million (down 611.9% YoY) and the FY2018 annual result came in at $138.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities slipped to -$64.7 million in Q2 2019, from $17.2 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $138.8 million in Q4 2018 to a low of -$64.7 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Milestone Pharmaceuticals | 43.40 Mn | -128.10 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | -64.72 Mn |
| Mar 31, 2019 | 17.20 Mn |
| Dec 31, 2018 | 138.76 Mn |
| Sep 30, 2018 | 2.03 Mn |
| Jun 30, 2018 | 12.64 Mn |
| Mar 31, 2018 | 12.64 Mn |